NYSE · Healthcare
agilon health, inc. (AGL)
As-reported financials and recent SEC filings for agilon health, inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$5.93B
Net income
$-391.3M
Net margin
-6.6%
Diluted EPS
—
ROE
-308.8%
P/E (TTM)
—
Market cap
$1.99B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.93B | $6.06B | $4.32B | $2.39B | $1.52B |
| Gross profit | — | — | — | — | — |
| Operating income | $-463.2M | $-292.1M | $-232.1M | $-105.4M | $-372.2M |
| Net income | $-391.3M | $-260.2M | $-262.6M | $-106.6M | $-406.5M |
| Diluted EPS | — | — | — | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-05
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →8-K2026-06-03
View on EDGAR →Go deeper on AGL
Search agilon health, inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.